Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis

Genotype II Clinical Trial

— TREXO  

Official title:

Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02863588
• Other study ID #: 6433
• Status: Terminated
• Phase: N/A
• Start date: March 30, 2017
• Est. completion date: November 11, 2019

Study information

• Verified date: August 2021
• Source: University Hospital, Strasbourg, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Ocular toxoplasmosis (OT) is a major cause of visual impairment worldwide. OT is responsible for 30 to 50% of posterior uveitis. It is characterized by dormant infections that may reactivate without known reasons, causing severe irreversible visual loss. The overall recurrence rate of OT in Europe is greater than 80% for patients and may range from one episode to 11 episodes (1% of OT) in the most extreme cases. Current treatments do not reduce the risk of recurrences and the risk of toxoplasmosis recurrence cannot be predicted in these immunocompetent patients. These clinical and biological expression changes might be related to an individual genetic susceptibility of each patient. The advanced analysis of the entire genome now possible to consider the project.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: November 11, 2019
• Est. primary completion date: November 11, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• seropositive for Toxoplasma gondii (for patient and parents)

• Infection with genotype II (for patient and parents)

• ocular toxoplasmosis recurrences >5 (patients only)

Exclusion Criteria:

• Parents seronegative for T. gondii infection

• Infection with others genotypes than type II

Related Conditions & MeSH terms

• Genetic Predisposition to Disease
• Genotype II
• Ocular Toxoplasmosis With Recurrences
• Recurrence
• Toxoplasmosis
• Toxoplasmosis Infection

Intervention

Biological:
• seropositive for Toxoplasma gondii
blood sample

Locations

Country	Name	City	State
France	University Hospital, Strasbourg, france	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Highlighting of genetic mutations associated with the susceptibility to Toxoplasma gondii.severe eye recurrences. Mutation analysis will be done by exome sequencing of the subjects included in this study		This analysis will be performed on a blood sample taken in patients included in the inclusion visit